Cardiometabolic conditions, such as type 2 diabetes and heart disease, have long been treated with pharmacologic interventions. Better Therapeutics believes cognitive behavioral therapy delivered through its prescription digital therapeutics platform, will provide better outcomes at a lower cost. We spoke to David Perry, co-founder and executive chairman of Better Therapeutics, about the company’s prescription digital therapeutics platform, the case for personalized cognitive behavior therapy delivered this way, and what it will take to get doctor to prescribe it and payers to reimburse for it.